Genetics and biology of pancreatic ductal adenocarcinoma, Genes Dev, vol.30, pp.355-85, 2016. ,
Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, pp.2403-2416, 1997. ,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1842, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
Immune escape mechanisms as a guide for cancer immunotherapy, Clin Cancer Res, vol.21, pp.687-92, 2015. ,
Immune evasion in pancreatic cancer: from mechanisms to therapy, Cancers (Basel), vol.10, issue.1, p.6, 2018. ,
Pancreatic cancer microenvironment, to target or not to target?, EMBO Mol Med, vol.8, pp.80-82, 2016. ,
The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-60, 2004. ,
Cancer-related inflammation, Nature, vol.454, pp.436-480, 2008. ,
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma, Br J Surg, vol.103, pp.1189-99, 2016. ,
Roles for KRAS in pancreatic tumor development and progression, Gastroenterology, vol.144, pp.1220-1229, 2013. ,
, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, vol.32, pp.185-203, 2017.
The immune network in pancreatic cancer development and progression, Oncogene, vol.33, pp.2956-67, 2014. ,
Immune infiltrates as predictive markers of survival in pancreatic cancer patients, Front Physiol, vol.4, p.210, 2013. ,
Role of immune cells in pancreatic cancer from bench to clinical application, Medicine, issue.49, p.5541, 2016. ,
CD8+ T cells are compromised in human pancreatic cancer, Transl Med, issue.2, p.105, 2012. ,
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer, Br J Cancer, vol.108, pp.914-937, 2013. ,
Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, vol.13, pp.2151-2158, 2007. ,
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002. ,
Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer, Pancreas, vol.32, pp.29-36, 2006. ,
Effects of perioperative immunonutrition on cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and Th17 response after pancreaticoduodenectomy, Surgery, vol.148, pp.573-81, 2010. ,
Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer, Oncotarget, vol.7, pp.66586-94, 2016. ,
Hypoxia inducible factor 1 (HIF-1) recruits macrophage to activate pancreatic Stellate cells in pancreatic ductal adenocarcinoma, Int J Mol Sci, vol.17, 2016. ,
Tumor-associated macrophages exhibit pro-and anti-inflammatory properties by which they impact on pancreatic tumorigenesis, Int J Cancer, vol.135, pp.843-61, 2014. ,
Significance of M2-polarized tumor-associated macrophage in pancreatic cancer, J Surg Res, vol.167, pp.211-220, 2011. ,
Role of tumorassociated macrophages in tumor progression and invasion, Cancer Metastasis Rev, vol.25, pp.315-337, 2006. ,
Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact, Cancer Sci, vol.106, pp.672-86, 2015. ,
Targeting tumor-associated macrophages to combat pancreatic cancer, Oncotarget, vol.7, pp.50735-54, 2016. ,
Tumour-associated macrophages as treatment targets in oncology, Nat Rev Clin Oncol, vol.14, pp.399-416, 2017. ,
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment, PLoS One, vol.9, p.96565, 2014. ,
Polarization of tumor-associated neutrophil (TAN) phenotype by TGF-?: "N1" versus "N2" TAN, Cancer Cell, vol.16, pp.183-94, 2009. ,
Neutrophil-derived proteases in the microenvironment of pancreatic cancer-active players in tumor progression, Int J Biol Sci, vol.12, pp.302-315, 2016. ,
Neutrophils in the tumor microenvironment, Trends Immunol, vol.37, pp.41-52, 2016. ,
Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment, Cancer Lett, vol.380, pp.253-259, 2016. ,
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, J Immunol, vol.172, pp.989-99, 2004. ,
Myeloid-derived suppressor cells and their role in pancreatic cancer, Cancer Gene Ther, vol.24, pp.100-105, 2017. ,
Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer, Oncol Lett, vol.12, pp.4477-84, 2016. ,
Mast cells: the Jekyll and Hyde of tumor growth, Trends Immunol, vol.25, pp.235-276, 2004. ,
Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer, Cancer Res, vol.73, pp.3927-3964, 2013. ,
Mast cells density positive to tryptase correlates with angiogenesis in pancreatic ductal adenocarcinoma patients having undergone surgery ,
, Gastroenterol Res Pract, p.951957, 2014.
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients, Pancreas, vol.33, pp.386-90, 2006. ,
The role of regulatory T cells in cancer immunology, Immunotargets Ther, vol.4, pp.159-71, 2015. ,
T(H)17 cells in tumour immunity and immunotherapy, Nat Rev Immunol, vol.10, pp.248-56, 2010. ,
Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients, Int J Mol Sci, vol.12, pp.7424-7461, 2011. ,
Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer, J Immunol, vol.185, pp.4063-71, 2010. ,
Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, vol.7, pp.211-218, 2005. ,
Th17 cell plasticity and functions in cancer immunity, Biomed Res Int, p.314620, 2015. ,
The paradox of Th17 cell functions in tumor immunity, Cell Immunol, vol.322, pp.15-25, 2017. ,
Th17 cells in cancer: the ultimate identity crisis, Front Immunol, vol.5, p.276, 2014. ,
Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients, Int J Clin Exp Pathol, vol.8, pp.5702-5710, 2015. ,
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer, J Exp Med, vol.208, pp.469-78, 2011. ,
?? T cells support pancreatic oncogenesis by restraining ?? T cell activation, Cell, vol.166, pp.1485-99, 2016. ,
BTN3A is a prognosis marker and a promising target for V?9V?2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma ,
, , vol.7, p.1372080, 2017.
Pancreatic tumors show high levels of hypoxia, Int J Radiat Oncol Biol Phys, vol.48, pp.919-941, 2000. ,
The hypoxic cell: a target for selective cancer therapy -eighteenth Bruce F. Cain Memorial Award Lecture, Cancer Res, vol.59, pp.5863-70, 1999. ,
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, vol.36, pp.439-484, 2017. ,
A combination of radiation and the hypoxia-activated prodrug evofosfamide (TH-302) is efficacious against a human orthotopic pancreatic tumor model, Transl Oncol, vol.10, pp.760-765, 2017. ,
Improved treatment of pancreatic cancer with drug delivery nanoparticles loaded with a novel AKT/PDK1 inhibitor, Pancreas, vol.45, pp.1158-66, 2016. ,
Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture, Gut, vol.43, pp.128-161, 1998. ,
Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis, Gut, vol.44, pp.534-575, 1999. ,
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma, Gastroenterology, vol.145, pp.1121-1153, 2013. ,
High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer, Int J Cancer, vol.130, pp.2337-2385, 2012. ,
Pancreatic cancer: PDAC subtypes, Nat Rev Cancer, vol.15, p.575, 2015. ,
Cancer immunotherapy comes of age, Nature, vol.480, pp.480-489, 2011. ,
Immunotherapy in pancreatic cancer: unleash its potential through novel combinations, World J Clin Oncol, vol.8, pp.230-270, 2017. ,
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation, Lancet, vol.346, pp.1399-400, 1995. ,
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice, Gastroenterology, vol.143, pp.1095-107, 2012. ,
The evolving role of immune checkpoint inhibitors in cancer treatment, Oncologist, vol.20, pp.812-834, 2015. ,
Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma, Cancer Immunol Res, vol.3, pp.399-411, 2015. ,
The origin and function of tumor-associated macrophages, Immunol Today, vol.13, pp.265-70, 1992. ,
Roles of regulatory T cells in cancer immunity, Int Immunol, vol.28, pp.401-410, 2016. ,
Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat Genet, vol.47, pp.1168-78, 2015. ,
Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, vol.531, pp.47-52, 2016. ,
Elements of cancer immunity and the cancer-immune set point, Nature, vol.541, pp.321-351, 2017. ,